- H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc ELOX to $1 from $2 and reiterated a Neutral rating.
- Analyst Andrew Fein says the ELX-02 top-line data "raises more questions than answers."
- Despite the "seemingly positive narrative put forward for the top-line data from ELX-02's Phase 2 top-line readout, we remain unconvinced," Fein tells investors in a research note.
- Related Link: Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors.
- Price Action: ELOX shares are down 12.40% at $0.76 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
